Cognition Therapeutics

This study is testing whether a new daily pill called CT1812 can slow the progression of early Alzheimer's disease. About 540 people with early memory problems will take either the drug or a placebo for 18 months. Researchers will measure changes in memory, thinking skills, and d…

This program provided the experimental drug CT1812 to people with mild-to-moderate Lewy body dementia for up to one year. The main goal was to gather more information about the drug's long-term safety and whether it helps control symptoms of this progressive brain disease. Partic…